ANSAID Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ansaid, and what generic alternatives are available?
Ansaid is a drug marketed by Pharmacia And Upjohn and is included in one NDA.
The generic ingredient in ANSAID is flurbiprofen. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the flurbiprofen profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ansaid
A generic version of ANSAID was approved as flurbiprofen by NEW HEIGHTSRX on May 31st, 1995.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for ANSAID?
- What are the global sales for ANSAID?
- What is Average Wholesale Price for ANSAID?
Summary for ANSAID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 142 |
| Clinical Trials: | 3 |
| Patent Applications: | 4,734 |
| DailyMed Link: | ANSAID at DailyMed |
Recent Clinical Trials for ANSAID
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Pfizer | Phase 1 |
| United States Army Research Institute of Environmental Medicine | Phase 1 |
| National Institute of Dental and Craniofacial Research (NIDCR) | Phase 2 |
US Patents and Regulatory Information for ANSAID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacia And Upjohn | ANSAID | flurbiprofen | TABLET;ORAL | 018766-002 | Oct 31, 1988 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Pharmacia And Upjohn | ANSAID | flurbiprofen | TABLET;ORAL | 018766-003 | Oct 31, 1988 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ANSAID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pharmacia And Upjohn | ANSAID | flurbiprofen | TABLET;ORAL | 018766-003 | Oct 31, 1988 | 3,793,457 | ⤷ Start Trial |
| Pharmacia And Upjohn | ANSAID | flurbiprofen | TABLET;ORAL | 018766-002 | Oct 31, 1988 | 3,755,427 | ⤷ Start Trial |
| Pharmacia And Upjohn | ANSAID | flurbiprofen | TABLET;ORAL | 018766-003 | Oct 31, 1988 | 3,755,427 | ⤷ Start Trial |
| Pharmacia And Upjohn | ANSAID | flurbiprofen | TABLET;ORAL | 018766-002 | Oct 31, 1988 | 3,793,457 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ANSAID
See the table below for patents covering ANSAID around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Belgium | 658723 | ⤷ Start Trial | |
| Switzerland | 454822 | Procédé de préparation d'acides carboxyliques thérapeutiquement actifs | ⤷ Start Trial |
| Switzerland | 501577 | Procédé de préparation d'acides phénylalcanoïques thérapeutiquement actifs (Biphenyl derivs antipyretic - analgesic antiinflammatory) | ⤷ Start Trial |
| Czechoslovakia | 163156 | ⤷ Start Trial | |
| Czechoslovakia | 163157 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
DrugChatter Q&A for ANSAID
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch